Effects of Sunitinib in the Expression of VEGF and of Interleukin 8: Explanation of Anti-angiogenic Effects.
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Biomarker; Therapeutic Use
- Acronyms SUVEGIL
- 22 Mar 2018 Results assessing effect of angiogenic treatment on VE cadherin post translational modifications using patient data from SUVEGIL and TORAVA trials published in the British Journal of Cancer
- 29 Aug 2017 Results (n=99) of SUVEGIL and TORAVA trials ,published in the British Journal of Cancer.
- 10 Jun 2017 Biomarkers information updated